Nov 6 (Reuters) - U.S. drugmaker Mylan NV reported a 2.3 percent decline in third-quarter revenue on Monday, hurt by lower sales in North America.
The company’s net earnings were $88.3 million, or 16 cents per share, in the quarter ended Sept. 30, compared with a loss of $119.8 million, or 23 cents per share, a year earlier.
The year-ago quarter included litigation-related expenses of $558 million.
Total revenue fell to $2.99 billion from $3.06 billion. (Reporting by Tamara Mathias in Bengaluru; Editing by Sriraj Kalluvila)